Black Arrow Biotech

Black Arrow Biotech is a private, preclinical-stage company founded in 2020 that combines artificial intelligence with peptide therapeutics. Its proprietary AI platform, JÜRI, is claimed to accelerate the discovery and optimization of therapeutic peptides by over 45x compared to conventional methods. The company has an internal lead program, BAC2539, an RNA-based therapy for cancer, and also offers AI-powered screening and peptide library services to external researchers. While demonstrating promising early validation through academic collaboration, the company is pre-revenue and faces the typical risks of an early-stage AI-biotech hybrid.

JÜRI: A proprietary artificial intelligence platform designed for the rapid generation, screening, and optimization of novel therapeutic peptides. It uses iterative learning from experimental data to improve candidate selection, claiming a >45x speed acceleration over conventional methods.

Competes with other AI-native biotechs like Exscientia, Recursion, and Insilico Medicine, as well as biotechs focused on peptide/RNA therapeutics. Differentiation hinges on the specialized performance of JÜRI for peptide discovery and the early validation of its lead candidate.